Payload Information

General Information of This Payload

Payload ID	PAY0ZLSTM
Name	SC-DR002
Synonyms	SC DR002; SCDR002 Click to Show/Hide
Target(s)	Human Deoxyribonucleic acid (hDNA)			Target Info
Formula	.
Isosmiles	.
InChI	.
InChIKey	.
IUPAC Name	.
Pharmaceutical Properties	Molecule Weight	.	Polar area	.
	Complexity	.	xlogp Value	.
	Heavy Count	.	Rot Bonds	.
	Hbond acc	.	Hbond Donor	.

Each Antibody-drug Conjugate Related to This Payload

Full Information of The Activity Data of The ADC(s) Related to This Payload

Tamrintamab pamozirine [Phase 1]

ADC Info

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Partial Response (PR)	1.72%
Patients Enrolled	Female patients (age 18 years) with EOC if they had evidence of progressive disease during or within 6 months of receiving a platinum regimen.
Administration Dosage	1 of 6 dose levels (0.025-0.40 mg/kg) every 3 weeks (Q3W), utilizing a standard 3+3 design (dose-limiting toxicity [DLT] period: 21 days).
*Related Clinical Trial*
NCT Number	NCT02539719	Phase Status	Phase 1
Clinical Description	A phase 1a/1b dose escalation and expansion study of SC-003 as a single-agent and in combination with ABBV-181 in subjects with platinum-resistant/ refractory ovarian cancer.
Primary Endpoint	The MTD for the Q3W schedule was 0.30 mg/kg and the SC-003 doses selected for the dose-expansion phase of the study were 0.30 mg/kg and 0.20 mg/kg.
Other Endpoint	ORR=5.17% (N=3/58), 3 patients achieved PR. All responses were observed at 0.20-0.30mg/kg. Responses were not durable, with only 1 PR confirmed on the follow-up 16-week scan.

References

Ref 1	Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study. Gynecol Oncol. 2020 Sep;158(3):640-645.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.